
PORTFOLIO QTR RETURN
5.4%
S&P 500 TOTAL RETURN
3.4%
ILLUMINA TOP GAINER
46.3%
RECURSION QTR REV
$7.7M
Moby Intelligence's "Longevity Portfolio" — a thematic bet on aging demographics and healthcare infrastructure — posted a 5.4% return from July 10 to October 9, 2026, outpacing the S&P 500 total return of 3.4% over the same period. The quarterly rebalance tells a sharper story than the headline number.
Extraction Map
The single swap is instructive: Insulet, maker of wearable insulin pumps, is out after two product recalls in a year, a revenue forecast cut, and a 16.1% drawdown. In its place comes Veeva Systems, whose stock surged 55.8% in the quarter despite still sitting 4% below its level a year prior. Veeva sells clinical-trial management and sales-force automation software to big pharma — described by Moby as "the profitable adult version" of their speculative AI-drug-discovery bet on Recursion Pharmaceuticals. Recursion itself stays in the portfolio but on a short leash: its allocation is cut from 3.45% to 2.0%. The company delivered quarterly revenue of just $7.7 million (roughly ¥1.19 billion), missed sales estimates substantially, runs at a loss, and exhibits volatility nearly three times the broader market. Every other holding sits at an equal 3.5% weight — a deliberately low-conviction, diversified posture across 28 names. Illumina led all holdings with a 46.3% gain, dragging the research-instruments cohort to the front. At the other end, UnitedHealth Group and CVS Health dropped 10.1% and 16.8% respectively, though both survive the cut — UnitedHealth on the strength of its third guidance raise this year, CVS presumably on valuation grounds. Tenet Healthcare rallied 29.1% after boosting profit forecasts by roughly 20%. Six holdings — Stryker, Jazz Pharmaceuticals, IDEXX Laboratories, Edwards Lifesciences, UnitedHealth, and CVS — underperformed the market by more than 10 percentage points. All six land on a January watchlist, a soft warning that amounts to probation without consequence. The portfolio's construction reveals its ideology: near-equal weighting across 29 names means no single thesis dominates. The mix spans Big Pharma stalwarts (Eli Lilly, Merck, J&J, Pfizer, AbbVie, Gilead), medical devices (Medtronic, Boston Scientific, Stryker, Edwards), diagnostics (Thermo Fisher, Agilent, Quest, Labcorp, IDEXX), healthcare delivery (UnitedHealth, CVS, Tenet, Ensign, Addus HomeCare), and two software/AI plays (Veeva, Recursion). It is a sector ETF with opinions. As a product, this is thematic portfolio content packaged behind a paywall — one of six Moby portfolios translated into Japanese by Business Insider Japan. The analysis is competent but light on risk disclosure and silent on fees, tracking error, or how a retail reader would actually replicate 29 equal-weighted positions with quarterly rebalancing. The real audience is engaged retail investors looking for healthcare-sector conviction, not institutional allocators.
Worth reading?
OPTIONAL
Score
44
/100
Mildly extractive — the portfolio content provides real sector analysis and stock-level reasoning, but is packaged behind a paywall with no discussion of execution costs, tracking error, or fee drag, creating an information asymmetry that benefits the publisher more than the reader.
What Is GRIN?
GRIN stands for Generativity, Resilience, Innovation efficiency, and Novelty openness. These four dimensions capture the essential characteristics of any memetic intelligence — whether a nation, a corporation, a religion, or a movement.
About GRINGenerativity
2/5
Resilience
3/5
Efficiency
2/5
Novelty
2/5
Extractive
3/5
Inverted
Does this create new capability or just redistribute existing value?
Modest generativity. Names specific stocks with specific reasoning (Insulet recalls, Veeva's SaaS margins), but no proprietary data or analytical edge beyond competent sector commentary available elsewhere.
Verified Facts (11)
Portfolio returned 5.4% from July 10 to October 9, vs S&P 500 total return of 3.4%
Illumina gained 46.3% in the quarter
Insulet fell 16.1% and had two product recalls within one year
Veeva Systems rose 55.8% in the quarter but remained ~4% below its year-ago level
Recursion Pharmaceuticals posted quarterly revenue of $7.7 million (~¥1.19 billion at ¥155/$)
Recursion's volatility is nearly 3x the broader market
UnitedHealth Group fell 10.1%, CVS Health fell 16.8%
UnitedHealth raised guidance for the third time this year on October 13
Tenet Healthcare raised profit forecasts by approximately one-fifth and subsequently rose 29.1%
Recursion allocation cut from 3.45% to 2.0%; all other holdings at 3.5%
Veeva is the only new addition across all six Moby portfolios
More latest news
Read all